NCT06533475View on ClinicalTrials.gov

A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 6, 2024

Primary Completion Date

November 17, 2024

Study Completion Date

November 17, 2024

Conditions
Healthy Participants
Interventions
DRUG

Minzasolmin tablet formulation under fasting condition

Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fasting condition

DRUG

Minzasolmin Granules in capsule under fasting condition

Drug: Minzasolmin Pharmaceutical form: Granules in capsule under fasting condition

DRUG

Minzasolmin tablet formulation under fed condition

Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fed condition

Trial Locations (1)

Unknown

Up0152 1001, Berlin

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT06533475 - A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants | Biotech Hunter | Biotech Hunter